Skip to content

Study Details

Orvepitant: A study to Reduce Severe Coughing for People with Idiopathic Pulmonary Fibrosis (IPF)

(IRB#: IRB_00152984)

Idiopathic pulmonary fibrosis (IPF) is a condition that causes scarring of the lungs and severe coughing. Orvepitant is a study drug to reduce chronic coughing for people with IPF. Research is needed to learn the safety and effectiveness of the study drug. Our hope is to provide long-lasting control of chronic cough and a better quality-of-life. The information we gain may aid future patients.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 40 years and older
  • Diagnosis of IPF
  • Cough associated with IPF
  • If taking pirfenidone or nintedanib, the dose must have been stable for at least 3 months
  • Agree to use specific birth control methods if applicable

Exclusion Criteria

  • Recent respiratory tract infection
  • Recent acute exacerbation of IPF
  • Current smokers or smokers who have quit in the last 6 months
  • Specific mental health conditions
  • Pregnant

Will I be paid for my time?


For more information contact:

Chloe Kirkpatrick


IRB#: IRB_00152984

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2022-12-14 07:00:00

Specialties: Pulmonary

Last Updated: 6/8/23